Back to MPT Database

VivaGel® Vaginal Gel

VivaGel® is an innovative technology being applied to a range of sexual/women’s health products by Starpharma and its partners, including for treatment & prevention of bacterial vaginosis and prevention of sexually transmitted infections. VivaGel® (SPL7013, or astodrimer sodium) is antiviral and blocks bacteria.  It is formulated as a mucoadhesive gel and delivered vaginally. Several clinical studies have successfully tested the safety and efficacy of VivaGel®.  

Development Stage:

Clinical – Phase 3 Trial (C3), Registered/ Marketed in Europe, the UK, Australia, New Zealand, South Africa, Singapore, and Indonesia (INT)

Hormonal/Non-Hormonal:

Non-Contraceptive

Delivery Route & Method:

Topical - Gel-Vaginal

Mechanism of Action:

Sulfonated dendrimer providing inhibition of viruses and bacteria; biofilm disruption

Developer:

  • Starpharma Pty Limited

Funding:

  • Starpharma Pty Limited

Funding Mechanism:

Income from sales; capital raising

Past Funding:

National Institutes of Health (NIH)

Active Ingredient(s):

  • SPL7013 (Astodrimer Sodium)

Product Indication(s):

  • Bacterial Vaginosis (BV)
  • HIV
  • HPV
  • HSV-2

Useful Links:

Back to MPT Database